Dr Reddy's Q4 Results: Profit Dhadaam Dhadaam Gira! Investors Mein Chinta Ka Mahaul

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Dr Reddy's Q4 Results: Profit Dhadaam Dhadaam Gira! Investors Mein Chinta Ka Mahaul
Overview

Dr Reddy's Laboratories ke investors ke liye yeh Q4 results disappoint karne wale hain. Company ka net profit **86%** tak gir gaya, jo **₹220 Crore** pe aa gaya. Revenue bhi **12%** neeche gaya, **₹7561 Crore** raha.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Profit Kyun Gira Itna? (Reasons for Profit Drop)

Is 86% ki badi girti hui profit ka sabse bada reason hai lenalidomide naam ki ek important drug ki sales mein kami. Iske saath hi, company ko kuch one-off expenses bhi aaye hain, jinhone earnings par asar dala. Co-Chairman & MD, G V Prasad ne kaha ki market mein challenges hain, par branded business ki strong performance aur currency mein positive moves ne thodi help ki hai.

Aage Ka Plan Kya Hai? (Strategy for Future Growth)

Quarter ke numbers ke baad bhi, Dr Reddy's management future profitability par focus kar raha hai. Prasad ne bataya ki ek two-pronged strategy follow ki jayegi: pehle, cost savings se core business ko mazboot karna aur doosre, product portfolio ko optimize karna. Company biosimilars, consumer health, aur new drug development jaisi growth areas mein bhi invest kar rahi hai taaki long-term value badh sake aur margins improve hon.

Results aane ke baad, 12 May, 2025 ko Dr Reddy's ka share Bombay Stock Exchange par 0.75% neeche band hua, jo ₹1270.10 tha.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.